PGX-CYP2D6 StripAssay®
CYP2D6 Metabolizer Status Genotyping
The PGX-CYP2D6 StripAssay® detects common CYP2D6 variants with impaired enzyme activity. As one of the most important liver enzymes in xenobiotic metabolism, CYP2D6 defects can cause severe adverse drug reactions from accumulation.
Key Features
Common Variant Detection
Detects common CYP2D6 variants with impaired enzyme activity affecting drug metabolism and patient safety.
Adverse Reaction Prevention
Enables patients with defective CYP2D6 variants to avoid severe adverse reactions from drug accumulation.
Major Liver Enzyme Coverage
CYP2D6 is involved in the metabolism of approximately 25% of all clinically used drugs.
Reverse Hybridization Technology
Based on reverse hybridization of biotinylated PCR products for reliable metabolizer status determination.
For Research Use Only (RUO)
PGX-CYP2D6 StripAssay® is intended for research use only in the United States and is not FDA-cleared for diagnostic use.